Data sharing statement Data described in the manuscript, code book, and analytic code will be made available upon request pending application and approval
Phase II typically funds up to $1,000,000 to $1,500,000 for 24-36 months to continue the R&D effort from the completed Phase I project and work towards a prototype demonstration
CorepH-SmartCoated Capsulesare programmed to completely bypass the stomach's destructive acids, for a targeted delivery direct into the bloodstream, from within the core of the GI Tract
Blekkenhorst, [email protected] This article was submitted to Translational Pharmacology, a section of the journal Frontiers in Pharmacology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Criteria for prescription weight loss medications are determined when the U.S